<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRAVACHOL- pravastatin sodiumÂ tabletÂ </strong><br>E.R. Squibb &amp; Sons, L.L.C.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use PRAVACHOL safely and effectively. See full prescribing information for PRAVACHOL.<br><br><br>PRAVACHOL<span class="Sup">Â®</span> (pravastatin sodium) Tablets
      <br>Initial U.S. Approval: 1991</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">PRAVACHOL is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: </p>
<ul class="Disc">
<li>Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. <a href="#s1.1">(1.1)</a>
</li>
<li>Reduce the risk of total mortality by reducing coronary <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, revascularization, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/TIA, and the progression of <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span> in patients with clinically evident CHD. <a href="#s1.1">(1.1)</a>
</li>
<li>Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. <a href="#s1.2">(1.2)</a>
</li>
<li>Reduce elevated serum TG levels in patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. <a href="#s1.2">(1.2)</a>
</li>
<li>Treat patients with primary dysbetalipoproteinemia who are not responding to diet. <a href="#s1.2">(1.2)</a>
</li>
<li>Treat children and adolescent patients ages 8 years and older with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> after failing an adequate trial of diet therapy. <a href="#s1.2">(1.2)</a>
</li>
</ul>
<p class="Highlighta">Limitations of use:  </p>
<ul class="Disc"><li>PRAVACHOL has not been studied in <span class="Italics">Fredrickson</span> Types I and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>. <a href="#s1.3">(1.3)</a>
</li></ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Adults: the recommended starting dose is 40 mg once daily. Use 80 mg dose only for patients not reaching LDL-C goal with 40 mg. <a href="#s2.2">(2.2)</a>
</li>
<li>Significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: the recommended starting dose is 10 mg once daily. <a href="#s2.2">(2.2)</a>
</li>
<li>Children (ages 8 to 13 years, inclusive): the recommended starting dose is 20 mg once daily. <a href="#s2.3">(2.3)</a>
</li>
<li>Adolescents (ages 14 to 18 years): the recommended starting dose is 40 mg once daily. <a href="#s2.3">(2.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 10 mg, 20 mg, 40 mg, 80 mg. <a href="#s3">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication. <a href="#s4.1">(4.1</a>, <a href="#s6.2">6.2</a>, <a href="#s11">11)</a>
</li>
<li>Active liver disease or unexplained, persistent elevations of serum transaminases. <a href="#s4.2">(4.2</a>, <a href="#s5.2">5.2)</a>
</li>
<li>Women who are pregnant or may become pregnant. <a href="#s4.3">(4.3</a>, <a href="#s8.1">8.1)</a>
</li>
<li>Nursing mothers. <a href="#s4.4">(4.4</a>, <a href="#s8.3">8.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>): predisposing factors include advanced age (â‰¥65), uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients should be advised to promptly report to their physician any unexplained and/or persistent <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Pravastatin therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. <a href="#s5.1">(5.1</a>, <a href="#s8.5">8.5)</a>
</li>
<li>Liver enzyme abnormalities: persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. <a href="#s5.2">(5.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">In short-term clinical trials, the most commonly reported adverse reactions (â‰¥2% and &gt; placebo) regardless of causality were: <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <a href="#s6.1">(6.1)</a>
								Â <br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Concomitant lipid-lowering therapies: use with fibrates or lipid-modifying doses (â‰¥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with PRAVACHOL. <a href="#s7">(7)</a>
</li>
<li>Cyclosporine: combination increases exposure. Limit pravastatin to 20 mg once daily. <a href="#s2.5">(2.5</a>, <a href="#s7.1">7.1)</a>
</li>
<li>Clarithromycin: combination increases exposure. Limit pravastatin to 40 mg once daily. <a href="#s2.6">(2.6</a>, <a href="#s7.2">7.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1  Prevention of Cardiovascular Disease</a></h2>
<h2><a href="#section-1.2" class="toc">1.2  <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3  Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Adult Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Pediatric Patients</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Concomitant Lipid-Altering Therapy</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Dosage in Patients Taking Cyclosporine</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Dosage in Patients Taking Clarithromycin</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Liver</a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Pregnancy</a></h2>
<h2><a href="#section-4.4" class="toc">4.4 Nursing Mothers</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Skeletal Muscle</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Liver</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Endocrine Function</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Adverse Clinical Events</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Laboratory Test Abnormalities</a></h2>
<h2><a href="#section-6.4" class="toc">6.4  Pediatric Patients</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Cyclosporine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  Clarithromycin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  Colchicine</a></h2>
<h2><a href="#section-7.4" class="toc">7.4  Gemfibrozil</a></h2>
<h2><a href="#section-7.5" class="toc">7.5  Other Fibrates</a></h2>
<h2><a href="#section-7.6" class="toc">7.6  Niacin</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Prevention of Coronary Heart Disease</a></h2>
<h2><a href="#section-13.2" class="toc">14.2  Secondary Prevention of Cardiovascular Events</a></h2>
<h2><a href="#section-13.3" class="toc">14.3  Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (<span class="Italics">Fredrickson</span> Types IIa and IIb)</a></h2>
<h2><a href="#section-13.4" class="toc">14.4  <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (<span class="Italics">Fredrickson</span> Type IV)</a></h2>
<h2><a href="#section-13.5" class="toc">14.5  Dysbetalipoproteinemia (<span class="Italics">Fredrickson</span> Type III)</a></h2>
<h2><a href="#section-13.6" class="toc">14.6  Pediatric Clinical Study</a></h2>
<h1><a href="#section-14" class="toc">15  REFERENCES<br></a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1  How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2  Storage</a></h2>
<h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures alone has been inadequate. </p>
<div class="Section" data-sectionCode="34067-9">
<a name="s1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1  Prevention of Cardiovascular Disease</h2>
<p class="First">In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), PRAVACHOL (pravastatin sodium) is indicated to:</p>
<ul class="Disc">
<li>reduce the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI).</li>
<li>reduce the risk of undergoing myocardial revascularization procedures.</li>
<li>reduce the risk of cardiovascular mortality with no increase in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from non-cardiovascular causes.</li>
</ul>
<p>In patients with clinically evident CHD, PRAVACHOL is indicated to:</p>
<ul class="Disc">
<li>reduce the risk of total mortality by reducing coronary <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>reduce the risk of MI.</li>
<li>reduce the risk of undergoing myocardial revascularization procedures.</li>
<li>reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>/transient ischemic attack (TIA).</li>
<li>slow the progression of <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2  <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></h2>
<p class="First">PRAVACHOL is indicated:</p>
<ul class="Disc">
<li>as an adjunct to diet to reduce elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (Total-C), low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> (<span class="Italics">Fredrickson</span> Types IIa and IIb).<span class="Sup">1</span>
</li>
<li>as an adjunct to diet for the treatment of patients with elevated serum TG levels (<span class="Italics">Fredrickson </span>Type IV).</li>
<li>for the treatment of patients with primary dysbetalipoproteinemia (<span class="Italics">Fredrickson</span> Type III) who do not respond adequately to diet.</li>
<li>as an adjunct to diet and lifestyle modification for treatment of <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present:
										<ol class="Littlealpha">
<li>LDL-C remains â‰¥190 mg/dL or</li>
<li>LDL-C remains â‰¥160 mg/dL and:
										<ul class="Alpha">
<li>there is a positive family history of premature cardiovascular disease (CVD) or</li>
<li>two or more other CVD risk factors are present in the patient.</li>
</ul>
</li>
</ol>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3  Limitations of Use</h2>
<p class="First">PRAVACHOL has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (<span class="Italics">Fredrickson</span> Types I and V).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information</h2>
<p class="First">The patient should be placed on a standard <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering diet before receiving PRAVACHOL and should continue on this diet during treatment with PRAVACHOL [see NCEP Treatment Guidelines for details on dietary therapy].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Adult Patients</h2>
<p class="First">The recommended starting dose is 40 mg once daily. If a daily dose of 40 mg does not achieve desired <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels, 80 mg once daily is recommended. In patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a starting dose of 10 mg daily is recommended. PRAVACHOL can be administered orally as a single dose at any time of the day, with or without food. Since the maximal effect of a given dose is seen within 4 weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patientâ€™s response to therapy and established treatment guidelines.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Pediatric Patients</h2>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.3.1"></a><a name="section-2.3.1"></a><p></p>
<h3>Children (Ages 8 to 13 Years, Inclusive)</h3>
<p class="First">The recommended dose is 20 mg once daily in children 8 to 13 years of age. Doses greater than 20 mg have not been studied in this patient population.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.3.2"></a><a name="section-2.3.2"></a><p></p>
<h3>Adolescents (Ages 14 to 18 Years)</h3>
<p class="First">The recommended starting dose is 40 mg once daily in adolescents 14 to 18 years of age. Doses greater than 40 mg have not been studied in this patient population.</p>
<p>Children and adolescents treated with pravastatin should be reevaluated in adulthood and appropriate changes made to their <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering regimen to achieve adult goals for LDL-C [see <span class="Italics"><a href="#s1.2">Indications and Usage (1.2)</a></span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Concomitant Lipid-Altering Therapy</h2>
<p class="First">PRAVACHOL may be used with bile acid resins. When administering a bile-acid-binding resin (e.g., cholestyramine, colestipol) and pravastatin, PRAVACHOL should be given either 1 hour or more before or at least 4 hours following the resin. [See <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Dosage in Patients Taking Cyclosporine</h2>
<p class="First">In patients taking immunosuppressive drugs such as cyclosporine concomitantly with pravastatin, therapy should begin with 10 mg of pravastatin sodium once-a-day at bedtime and titration to higher doses should be done with caution. Most patients treated with this combination received a maximum pravastatin sodium dose of 20 mg/day. In patients taking cyclosporine, therapy should be limited to 20 mg of pravastatin sodium once daily [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#s7.1">Drug Interactions (7.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Dosage in Patients Taking Clarithromycin</h2>
<p class="First">In patients taking clarithromycin, therapy should be limited to 40 mg of pravastatin sodium once daily [see <span class="Italics"><a href="#s7.2">Drug Interactions (7.2)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Bold">PRAVACHOL</span><span class="Sup">Â®</span><span class="Bold"> Tablets</span> are
supplied as:</p>
<p><span class="Bold">10 mg tablets:</span> Pink to peach,
rounded, rectangular-shaped, biconvex with a â€œPâ€? embossed on one side and
â€œPRAVACHOL 10â€? engraved on the opposite side.</p>
<p><span class="Bold">20
mg tablets:</span> Yellow, rounded, rectangular-shaped, biconvex with a â€œPâ€?
embossed on one side and â€œPRAVACHOL 20â€? engraved on the opposite side.</p>
<p><span class="Bold">40
mg tablets:</span> Green, rounded, rectangular-shaped, biconvex with a â€œPâ€?
embossed on one side and â€œPRAVACHOL 40â€? engraved on the opposite side.</p>
<p><span class="Bold">80
mg tablets:</span> Yellow, oval-shaped tablet with â€œBMSâ€? on one side and â€œ80â€?
on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="34070-3">
<a name="s4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this
medication.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Liver</h2>
<p class="First">Active liver disease or unexplained, persistent elevations of serum transaminases [see <span class="Italics"><a href="#s5.2">Warnings
and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Pregnancy</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and other products of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since statins decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, they are contraindicated during pregnancy and in nursing mothers. PRAVASTATIN SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this class of drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see <span class="Italics"><a href="#s8.1">Use in Specific Populations (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4.4"></a><a name="section-4.4"></a><p></p>
<h2>4.4 Nursing Mothers</h2>
<p class="First">A small amount of pravastatin is excreted in human breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require PRAVACHOL treatment should not breast-feed their infants [see <span class="Italics"><a href="#s8.3">Use in Specific Populations (8.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Skeletal Muscle</h2>
<p class="First"><span class="Bold">Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported with pravastatin and other drugs in this class.</span> A history of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may be a risk factor for the development of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Such patients merit closer monitoring for skeletal muscle effects.</p>
<p>Uncomplicated <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> has also been reported in pravastatin-treated patients [see <span class="Italics"><a href="#s6">Adverse Reactions (6)</a></span>]. <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>, defined as muscle aching or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN), was rare (&lt;0.1%) in pravastatin clinical trials. <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> should be considered in any patient with diffuse <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, muscle <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and/or marked elevation of CPK. Predisposing factors include advanced age (â‰¥65), uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (IMNM), an autoimmune <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, associated with statin use. IMNM is characterized by: proximal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and elevated serum CPK, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> without significant <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and improvement with immunosuppressive agents.</p>
<p>All patients should be advised to promptly report to their physician unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if muscle signs and symptoms persist after discontinuing PRAVACHOL.</p>
<p><span class="Bold">Pravastatin therapy should be discontinued if markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. Pravastatin therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, e.g., <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; major surgery; <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.</span></p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with statins is increased with concurrent therapy with either erythromycin, cyclosporine, niacin, or fibrates. However, neither <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> nor significant increases in CPK levels have been observed in 3 reports involving a total of 100 post-transplant patients (24 renal and 76 cardiac) treated for up to 2 years concurrently with pravastatin 10 to 40 mg and cyclosporine. Some of these patients also received other concomitant immunosuppressive therapies. Further, in clinical trials involving small numbers of patients who were treated concurrently with pravastatin and niacin, there were no reports of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. Also, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> was not reported in a trial of combination pravastatin (40 mg/day) and gemfibrozil (1200 mg/day), although 4 of 75 patients on the combination showed marked CPK elevations versus 1 of 73 patients receiving placebo. There was a trend toward more frequent CPK elevations and patient withdrawals due to musculoskeletal symptoms in the group receiving combined treatment as compared with the groups receiving placebo, gemfibrozil, or pravastatin monotherapy.<span class="Bold"> The use of fibrates alone may occasionally be associated with <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. The benefit of further alterations in lipid levels by the combined use of PRAVACHOL with fibrates should be carefully weighed against the potential risks of this combination.</span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with pravastatin coadministered with colchicine, and caution should be exercised when prescribing pravastatin with colchicine [see <span class="Italics"><a href="#s7.3">Drug Interactions (7.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Liver</h2>
<p class="First">Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. In 3 long-term (4.8-5.9 years), placebo-controlled clinical trials (WOS, LIPID, CARE), 19,592 subjects (19,768 randomized) were exposed to pravastatin or placebo [see  <span class="Italics"><a href="#s14">Clinical Studies (14)</a></span>]. In an analysis of serum transaminase values (ALT, AST), incidences of marked abnormalities were compared between the pravastatin and placebo treatment groups; a marked abnormality was defined as a post-treatment test value greater than 3 times the upper limit of normal for subjects with pretreatment values less than or equal to the upper limit of normal, or 4 times the pretreatment value for subjects with pretreatment values greater than the upper limit of normal but less than 1.5 times the upper limit of normal. Marked abnormalities of ALT or AST occurred with similar low frequency (â‰¤1.2%) in both treatment groups. Overall, clinical trial experience showed that liver function test abnormalities observed during pravastatin therapy were usually asymptomatic, not associated with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, and did not appear to be related to treatment duration. In a 320-patient placebo-controlled clinical trial, subjects with chronic (&gt;6 months) stable liver disease, due primarily to <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C or non-<span class="product-label-link" type="condition" conceptid="193256" conceptname="Alcoholic fatty liver">alcoholic fatty liver</span> disease, were treated with 80 mg pravastatin or placebo for up to 9 months. The primary safety endpoint was the proportion of subjects with at least one ALT â‰¥2 times the upper limit of normal for those with normal ALT (â‰¤ the upper limit of normal) at baseline or a doubling of the baseline ALT for those with elevated ALT (&gt; the upper limit of normal) at baseline. By Week 36, 12 out of 160 (7.5%) subjects treated with pravastatin met the prespecified safety ALT endpoint compared to 20 out of 160 (12.5%) subjects receiving placebo. Conclusions regarding liver safety are limited since the study was not large enough to establish similarity between groups (with 95% confidence) in the rates of ALT elevation.</p>
<p><span class="Bold">It is recommended that liver function tests be performed prior to the initiation of therapy and when clinically indicated.</span></p>
<p>Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of pravastatin [see <span class="Italics"><a href="#s4.2">Contraindications (4.2)</a></span>]. Caution should be exercised when pravastatin is administered to patients who have a recent (&lt;6 months) history of liver disease, have signs that may suggest liver disease (e.g., unexplained aminotransferase elevations, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>), or are heavy users of alcohol. </p>
<p>There have been rare postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking statins, including pravastatin. If serious <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with clinical symptoms and/or <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs during treatment with PRAVACHOL, promptly interrupt therapy. If an alternate etiology is not found do not restart PRAVACHOL.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Endocrine Function</h2>
<p class="First">Statins interfere with <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and lower circulating <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production. Results of clinical trials with pravastatin in males and post-menopausal females were inconsistent with regard to possible effects of the drug on basal steroid hormone levels. In a study of 21 males, the mean testosterone response to human chorionic gonadotropin was significantly reduced (p&lt;0.004) after 16 weeks of treatment with 40 mg of pravastatin. However, the percentage of patients showing a â‰¥50% rise in plasma testosterone after human chorionic gonadotropin stimulation did not change significantly after therapy in these patients. The effects of statins on spermatogenesis and fertility have not been studied in adequate numbers of patients. The effects, if any, of pravastatin on the pituitary-gonadal axis in pre-menopausal females are unknown. Patients treated with pravastatin who display clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should also be exercised if a statin or other agent used to lower <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.</p>
<p>In a placebo-controlled study of 214 pediatric patients with HeFH, of which 106 were treated with pravastatin (20 mg in the children aged 8-13 years and 40 mg in the adolescents aged 14-18 years) for 2 years, there were no detectable differences seen in any of the endocrine parameters (ACTH, cortisol, DHEAS, FSH, LH, TSH, estradiol [girls] or testosterone [boys]) relative to placebo. There were no detectable differences seen in height and weight changes, testicular volume changes, or Tanner score relative to placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Pravastatin is generally well tolerated; adverse reactions have usually been mild and transient. In 4-month-long placebo-controlled trials, 1.7% of pravastatin-treated patients and 1.2% of placebo-treated patients were discontinued from treatment because of adverse experiences attributed to study drug therapy; this difference was not statistically significant. </p>
<div class="Section" data-sectionCode="34084-4">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Adverse Clinical Events</h2>
<div class="Section" data-sectionCode="34084-4">
<a name="s6.1.1"></a><a name="section-6.1.1"></a><p></p>
<h3>Short-Term Controlled Trials</h3>
<p class="First">In the PRAVACHOL placebo-controlled clinical trials database of 1313 patients (age range 20-76 years, 32.4% women, 93.5% Caucasians, 5% Blacks, 0.9% Hispanics, 0.4% Asians, 0.2% Others) with a median treatment duration of 14 weeks, 3.3% of patients on PRAVACHOL and 1.2% patients on placebo discontinued due to adverse events regardless of causality. The most common adverse reactions that led to treatment discontinuation and occurred at an incidence greater than placebo were: liver function test increased, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>/<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>All adverse clinical events (regardless of causality) reported in â‰¥2% of pravastatin-treated patients in placebo-controlled trials of up to 8 months duration are identified in Table 1:</p>
<a name="st1"></a><table border="0" cellpadding="2" cellspacing="1" frame="above" width="100%">
<caption><span>Table 1: Adverse Events in â‰¥2% of Patients Treated with Pravastatin
5 to 40 mg and at an Incidence Greater Than Placebo in Short-Term Placebo-Controlled Trials (% of patients)</span></caption>
<colgroup>
<col width="25%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="Bold">Body
System/Event</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">5 mg<br>N=100</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">10 mg<br>N=153</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">20 mg<br>N=478</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">40 mg<br>N=171</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Any Dose<br>N=902</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Placebo<br>N=411</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">Cardiovascular<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">5.0</td>
<td class="Botrule Rrule" align="center" valign="bottom">4.6</td>
<td class="Botrule Rrule" align="center" valign="bottom">4.8</td>
<td class="Botrule Rrule" align="center" valign="bottom">3.5</td>
<td class="Botrule Rrule" align="center" valign="bottom">4.5</td>
<td class="Botrule Rrule" align="center" valign="bottom">3.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Dermatologic<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">3.0</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.6</td>
<td class="Botrule Rrule" align="center" valign="bottom">6.7</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.2</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">4.5</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Gastrointestinal<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>/<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal Distension</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<br>4.0<br>8.0<br>2.0<br>0.0<br>2.0</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>5.9<br>8.5<br>3.3<br>3.3<br>3.3</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>10.5<br>6.5<br>4.6<br>3.6<br>2.1</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2.3<br>4.7<br>0.0<br>0.6<br>0.6</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>7.4<br>6.7<br>3.2<br>2.5<br>2.0</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>7.1<br>5.6<br>4.4<br>2.7<br>2.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">General<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>4.0<br>4.0<br>4.0</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>1.3<br>1.3<br>2.6</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>5.2<br>3.3<br>1.9</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>0.0<br>1.2<br>0.6</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>3.4<br>2.7<br>2.0</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>3.9<br>1.9<br>0.7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Musculoskeletal<br>Â Â Â Â Musculoskeletal
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">13.0<br>1.0</td>
<td class="Botrule Rrule" align="center" valign="bottom">3.9<br>2.6</td>
<td class="Botrule Rrule" align="center" valign="bottom">13.2<br>2.9</td>
<td class="Botrule Rrule" align="center" valign="bottom">5.3<br>1.2</td>
<td class="Botrule Rrule" align="center" valign="bottom">10.1<br>2.3</td>
<td class="Botrule Rrule" align="center" valign="bottom">10.2<br>1.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Nervous SystemÂ Â Â Â <br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">5.0<br>4.0</td>
<td class="Botrule Rrule" align="center" valign="bottom">6.5<br>1.3</td>
<td class="Botrule Rrule" align="center" valign="bottom">7.5<br>5.2</td>
<td class="Botrule Rrule" align="center" valign="bottom">3.5<br>0.6</td>
<td class="Botrule Rrule" align="center" valign="bottom">6.3<br>3.5</td>
<td class="Botrule Rrule" align="center" valign="bottom">4.6<br>3.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Respiratory<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Infection</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">2.0<br>6.0<br>7.0<br>4.0</td>
<td class="Botrule Rrule" align="center" valign="bottom">4.6<br>9.8<br>5.2<br>1.3</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.5<br>5.2<br>3.8<br>3.1</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.2<br>4.1<br>1.2<br>1.2</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.0<br>5.9<br>3.9<br>2.5</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.7<br>5.8<br>4.9<br>1.7</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Investigation<br>Â Â Â Â ALT Increased<br>Â Â Â Â g-GT Increased<br>Â Â Â Â CPK Increased</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.0<br>3.0<br>5.0</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.0<br>2.6<br>1.3</td>
<td class="Botrule Rrule" align="center" valign="bottom">4.0<br>2.1<br>5.2</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.2<br>0.6<br>2.9</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.9<br>2.0<br>4.1</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.2<br>1.2<br>3.6</td>
</tr>
</tbody>
</table>
<p>The safety and tolerability of PRAVACHOL at a dose of 80 mg in 2 controlled trials with a mean exposure of 8.6 months was similar to that of PRAVACHOL at lower doses except that 4 out of 464 patients taking 80 mg of pravastatin had a single elevation of CK &gt;10 times ULN compared to 0 out of 115 patients taking 40 mg of pravastatin.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6.1.2"></a><a name="section-6.1.2"></a><p></p>
<h3>Long-Term Controlled Morbidity and Mortality Trials</h3>
<p class="First">In the PRAVACHOL placebo-controlled clinical trials database of 21,483 patients (age range 24-75 years, 10.3% women, 52.3% Caucasians, 0.8% Blacks, 0.5% Hispanics, 0.1% Asians, 0.1% Others, 46.1% Not Recorded) with a median treatment duration of 261 weeks, 8.1% of patients on PRAVACHOL and 9.3% patients on placebo discontinued due to adverse events regardless of causality.</p>
<p>Adverse event data were pooled from 7 double-blind, placebo-controlled trials (West of Scotland Coronary Prevention Study [WOS]; <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and Recurrent Events study [CARE]; Long-term Intervention with Pravastatin in Ischemic Disease study [LIPID]; Pravastatin Limitation of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> in the Coronary Arteries study [PLAC I]; Pravastatin, Lipids and <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> in the Carotids study [PLAC II]; Regression Growth Evaluation Statin Study [REGRESS]; and Kuopio <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> Prevention Study [KAPS]) involving a total of 10,764 patients treated with pravastatin 40 mg and 10,719 patients treated with placebo. The safety and tolerability profile in the pravastatin group was comparable to that of the placebo group. Patients were exposed to pravastatin for a mean of 4.0 to 5.1 years in WOS, CARE, and LIPID and 1.9 to 2.9 years in PLAC I, PLAC II, KAPS, and REGRESS. In these long-term trials, the most common reasons for discontinuation were mild, non-specific gastrointestinal complaints. Collectively, these 7 trials represent 47,613 patient-years of exposure to pravastatin. All clinical adverse events (regardless of causality) occurring in â‰¥2% of patients treated with pravastatin in these studies are identified in Table 2.</p>
<a name="st2"></a><table border="0" cellpadding="2" cellspacing="1" frame="above" width="100%">
<caption><span>Table 2: Adverse Events in â‰¥2% of Patients Treated with Pravastatin
40Â mg and at an Incidence Greater Than Placebo in Long-Term Placebo-Controlled Trials</span></caption>
<colgroup>
<col width="60%">
<col width="20%">
<col width="20%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Body
System/Event</span></th>
<th class="Botrule Rrule Toprule" align="center"><span class="Bold">Pravastatin<br>(N=10,764)<br>%
of patients</span></th>
<th class="Botrule Rrule Toprule" align="center"><span class="Bold">Placebo<br>(N=10,719)<br>%
of patients</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">Dermatologic<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (including <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>)</td>
<td class="Botrule Rrule" align="center">
<br>7.2</td>
<td class="Botrule Rrule" align="center">
<br>7.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">General<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span></td>
<td class="Botrule Rrule" align="center">
<br>3.0<br>8.4<br>10.0<br>2.1<br>3.8<br>3.3</td>
<td class="Botrule Rrule" align="center">
<br>2.7<br>7.8<br>9.8<br>1.9<br>3.3<br>2.8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Musculoskeletal<br>Â Â Â Â Musculoskeletal
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Cramp</span><br>Â Â Â Â Musculoskeletal Traumatism</td>
<td class="Botrule Rrule" align="center">
<br>24.9<br>5.1<br>10.2</td>
<td class="Botrule Rrule" align="center">
<br>24.4<br>4.6<br>9.6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Nervous System<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep Disturbance</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>/<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Botrule Rrule" align="center">
<br>7.3<br>3.0<br>4.8<br>3.2</td>
<td class="Botrule Rrule" align="center">
<br>6.6<br>2.4<br>4.7<br>3.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Renal/Genitourinary<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></td>
<td class="Botrule Rrule" align="center">
<br>2.7</td>
<td class="Botrule Rrule" align="center">
<br>2.6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Respiratory<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span><br>Â Â Â Â Pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br>Â Â Â Â Sinus Abnormality<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4028970" conceptname="Tracheobronchitis">Tracheobronchitis</span></td>
<td class="Botrule Rrule" align="center">
<br>21.2<br>8.2<br>9.2<br>3.8<br>7.0<br>3.4</td>
<td class="Botrule Rrule" align="center">
<br>20.2<br>7.4<br>9.0<br>3.5<br>6.7<br>3.1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Special Senses<br>Â Â Â Â Vision
Disturbance (includes <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>)</td>
<td class="Botrule Rrule" align="center">
<br>3.4</td>
<td class="Botrule Rrule" align="center">
<br>3.3</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infection</span></td>
<td class="Botrule Rrule" align="center">
<br>3.2</td>
<td class="Botrule Rrule" align="center">
<br>2.9</td>
</tr>
</tbody>
</table>
<p>In addition to the events listed above in the long-term trials table, events of probable, possible, or uncertain relationship to study drug that occurred in &lt;2.0% of pravastatin-treated patients in the long-term trials included the following:</p>
<p><span class="Italics">Dermatologic:</span> scalp hair abnormality (including <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Endocrine/Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, libido change.</p>
<p><span class="Italics">General:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>.</p>
<p><span class="Italics">Immunologic:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> head/neck.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</p>
<p><span class="Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>).</p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to the events reported above, as with other drugs in this class, the following events have been reported rarely during postmarketing experience with PRAVACHOL, regardless of causality assessment:</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>,
<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with statin use [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</p>
<p><span class="Italics">Nervous System:</span> dysfunction of certain cranial nerves (including alteration of taste, impairment of extraocular movement, <span class="product-label-link" type="condition" conceptid="434657" conceptname="Weakness of face muscles">facial paresis</span>), peripheral nerve <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">palsy</span>.</p>
<p>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>-like syndrome, <span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">polymyalgia rheumatica</span>, <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, positive ANA, ESR increase, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>).</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (including <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>), <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, fatty change in liver, cirrhosis, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span>, fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>.</p>
<p><span class="Italics">Dermatologic:</span> a variety of skin changes (e.g., <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, discoloration, dryness of mucous membranes, changes to hair/nails).</p>
<p><span class="Italics">Renal:</span> urinary abnormality (including <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, frequency, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>).</p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="Italics">Reproductive:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.</p>
<p><span class="Italics">Laboratory
Abnormalities:</span> liver function test abnormalities, thyroid function abnormalities.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Laboratory Test Abnormalities</h2>
<p class="First">Increases in ALT, AST values and CPK have been observed [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1,</a><a href="#s5.2"> 5.2)</a></span>].</p>
<p>Transient, asymptomatic <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> has been reported. Eosinophil counts usually returned to normal despite continued therapy. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> have been reported with statins.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4  Pediatric Patients</h2>
<p class="First">In a 2-year, double-blind, placebo-controlled
study involving 100 boys and 114 girls with HeFH (n=214; age range 8-18.5 years, 53% female, 95% Caucasians, &lt;1% Blacks, 3% Asians, 1% Other), the safety and tolerability profile of pravastatin was generally similar to that of placebo. [See <span class="Italics"><a href="#s5.3">Warnings and Precautions (5.3)</a></span>, <span class="Italics"><a href="#s8.4">Use in Specific Populations (8.4)</a></span>, and <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>.]</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Bold">For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> increases [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>].</span></p>
<div class="Section" data-sectionCode="34073-7">
<a name="s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Cyclosporine</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased with concomitant administration of cyclosporine. Limit pravastatin to 20 mg once daily for concomitant use with cyclosporine [see <span class="Italics"><a href="#s2.5">Dosage and Administration (2.5)</a></span>, <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>, and <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2  Clarithromycin</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased with concomitant administration of clarithromycin. Limit pravastatin to 40 mg once daily for concomitant use with clarithromycin [see <span class="Italics"><a href="#s2.6">Dosage and Administration (2.6)</a></span>, <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>, and <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3  Colchicine</h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased with concomitant administration of colchicine [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4  Gemfibrozil</h2>
<p class="First">Due to an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of PRAVACHOL with gemfibrozil should be avoided [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5  Other Fibrates</h2>
<p class="First">Because it is known that the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, PRAVACHOL should be administered with caution when used concomitantly with other fibrates [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6  Niacin</h2>
<p class="First">The risk of skeletal muscle effects may be enhanced when pravastatin is used in combination with niacin; a reduction in PRAVACHOL dosage should be considered in this setting [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s8.1.1"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category X</h3>
<p class="First">[See <span class="Italics"><a href="#s4.3">Contraindications (4.3)</a></span>.]</p>
<p>Safety in pregnant women has not been established. Available data in women inadvertently taking pravastatin while pregnant do not suggest any adverse clinical events. However, there are no adequate and well-controlled studies in pregnant women. Therefore, it is not known whether pravastatin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Pravastatin should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus and patients have been informed of the potential hazards.</p>
<p>Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review<span class="Sup">2</span> of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed what would be expected in the general population. The number of cases is adequate to exclude a â‰¥3- to 4-fold increase in congenital anomalies over the background incidence. In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. As safety in pregnant women has not been established and there is no apparent benefit to therapy with PRAVACHOL during pregnancy [see <span class="Italics"><a href="#s4.3">Contraindications (4.3)</a></span>], treatment should be immediately discontinued as soon as pregnancy is recognized. PRAVACHOL should be administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards.</p>
<p>Pravastatin was neither embryolethal nor teratogenic in rats at doses up to 1000 mg/kg daily or in rabbits at doses of up to 50 mg/kg daily. These doses resulted in 10 times (rabbit) or 120 times (rat) the human exposure at 80 mg/day maximum recommended human dose (MRHD) based on surface area (mg/m<span class="Sup">2</span>).</p>
<p>In pregnant rats given oral gavage doses of 4, 20, 100, 500, and 1000 mg/kg/day from gestation days 7 through 17 (organogenesis) increased mortality of offspring and skeletal anomalies were observed at 100 mg/kg/day systemic exposure, 10 times the human exposure at 80 mg/day MRHD based on body surface area (mg/m<span class="Sup">2</span>).</p>
<p>In pregnant rats given oral gavage doses of 10, 100, and 1000 mg/kg/day from gestation day 17 through lactation day 21 (weaning) increased mortality of offspring and <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> were observed at 100 mg/kg/day systemic exposure, 12 times the human exposure at 80 mg/day MRHD based on body surface area (mg/m<span class="Sup">2</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">A small amount of pravastatin is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants, women taking PRAVACHOL should not nurse [see <span class="Italics"><a href="#s4.4">Contraindications (4.4)</a></span>].</p>
<p>Pravastatin crosses the placenta and is found in fetal tissue at 30% maternal plasma levels following a single 20 mg/kg dose given to pregnant rats on gestation day 18. Similar studies in lactating rats indicate secretion of pravastatin into breast milk at 0.2 to 6.5 times higher levels than maternal plasma at exposures equivalent to 2 times human exposure at the MRHD.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of PRAVACHOL in children and adolescents from 8 to 18 years of age have been evaluated in a placebo-controlled study of 2 years duration. Patients treated with pravastatin had an adverse experience profile generally similar to that of patients treated with placebo with <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> commonly reported in both treatment groups. [See <span class="Italics"><a href="#s6.4">Adverse Reactions (6.4)</a></span>.] <span class="Bold">Doses greater than 40 mg have not been studied in this population. </span>Children and adolescent females of childbearing potential should be counseled on appropriate contraceptive methods while on pravastatin therapy [see <span class="Italics"><a href="#s4.3">Contraindications (4.3)</a></span> and <span class="Italics"><a href="#s8.1">Use in Specific Populations
(8.1)</a></span>]. For dosing information [see <span class="Italics"><a href="#s2.3">Dosage
and Administration (2.3)</a></span>.]</p>
<p>Double-blind, placebo-controlled pravastatin studies in children less than 8 years of age have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Two secondary prevention trials with pravastatin (CARE and LIPID) included a total of 6593 subjects treated with pravastatin 40 mg for periods ranging up to 6 years. Across these 2 studies, 36.1% of pravastatin subjects were aged 65 and older and 0.8% were aged 75 and older. The beneficial effect of pravastatin in elderly subjects in reducing cardiovascular events and in modifying lipid profiles was similar to that seen in younger subjects. The adverse event profile in the elderly was similar to that in the overall population. Other reported clinical experience has not identified differences in responses to pravastatin between elderly and younger patients.</p>
<p>Mean pravastatin AUCs are slightly (25%-50%) higher in elderly subjects than in healthy young subjects, but mean maximum plasma concentration (C<span class="Sub">max</span>), time to maximum plasma concentration (T<span class="Sub">max</span>),
and half-life (t<span class="Sub">Â½</span>) values are similar in both age groups and substantial
accumulation of pravastatin would not be expected in the elderly [see <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<p>Since advanced age (â‰¥65 years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, PRAVACHOL should be prescribed with caution in the elderly [see <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First">Pravastatin has not been evaluated in patients with rare <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span>. In this group of patients, it has been reported that statins are less effective because the patients lack functional LDL receptors.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">To date, there has been limited experience with overdosage of pravastatin. If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, it should be treated symptomatically with laboratory monitoring and supportive measures should be instituted as required.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">PRAVACHOL<span class="Sup">Â®</span> (pravastatin
sodium) is one of a class of lipid-lowering compounds, the statins, which reduce <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> biosynthesis. These agents are competitive
inhibitors of HMG-CoA reductase, the enzyme catalyzing the early rate-limiting
step in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> biosynthesis, conversion of HMG-CoA to mevalonate.</p>
<p>Pravastatin
sodium is designated chemically as 1-Naphthalene-heptanoic acid, 1,2,6,7,8,8a-hexahydro-Î²,Î´,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-,
monosodium salt, [1S-[1Î±(Î²S*,Î´S*),2Î±,6Î±,8Î²(R*),8aÎ±]]-.</p>
<p>Structural formula:</p>
<div class="Figure"><img alt="Pravachol Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=897ad8b7-921d-eb02-a61c-3419e662a2da&amp;name=pravachol-struct.jpg"></div>
<p>Pravastatin sodium is an odorless, white to off-white,
fine or crystalline powder. It is a relatively polar hydrophilic compound
with a partition coefficient (octanol/water) of 0.59 at a pH of 7.0. It is
soluble in methanol and water (&gt;300 mg/mL), slightly soluble in isopropanol,
and practically insoluble in acetone, acetonitrile, chloroform, and ether.</p>
<p>PRAVACHOL
is available for oral administration as 10 mg, 20 mg, 40 mg, and 80Â mg tablets.
Inactive ingredients include: croscarmellose sodium, lactose, magnesium oxide,
magnesium stearate, microcrystalline cellulose, and povidone. The 10 mg tablet
also contains Red Ferric Oxide, the 20 mg and 80 mg tablets also contain Yellow
Ferric Oxide, and the 40 mg tablet also contains Green Lake Blend (mixture
of D&amp;C Yellow No. 10-Aluminum Lake and FD&amp;C Blue No. 1-Aluminum Lake).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. In addition, pravastatin reduces VLDL and TG and increases HDL-C.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="43682-4">
<a name="s12.3.1"></a><a name="section-11.2.1"></a><p></p>
<h3>General</h3>
<p class="First"><span class="Bold">Absorption:</span> PRAVACHOL is administered orally in the active form. In studies in man, peak plasma pravastatin concentrations occurred 1 to 1.5 hours upon oral administration. Based on urinary recovery of total radiolabeled drug, the average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. While the presence of food in the gastrointestinal tract reduces systemic bioavailability, the lipid-lowering effects of the drug are similar whether taken with or 1 hour prior to meals.</p>
<p>Pravastatin plasma concentrations, including area under the concentration-time curve (AUC), C<span class="Sub">max</span>, and steady-state minimum (C<span class="Sub">min</span>), are directly proportional to administered dose. Systemic bioavailability of pravastatin administered following a bedtime dose was decreased 60% compared to that following an AM dose. Despite this decrease in systemic bioavailability, the efficacy of pravastatin administered once daily in the evening, although not statistically significant, was marginally more effective than that after a morning dose. </p>
<p>The coefficient of variation (CV), based on between-subject variability, was 50% to 60% for AUC. The geometric means of pravastatin C<span class="Sub">max</span> and AUC following a 20 mg dose in the fasted state were 26.5 ng/mL and 59.8 ng*hr/mL, respectively.</p>
<p>Steady-state AUCs, C<span class="Sub">max</span>, and C<span class="Sub">min</span> plasma concentrations showed no evidence of pravastatin accumulation following once or twice daily administration of PRAVACHOL tablets. </p>
<p><span class="Bold">Distribution:</span> Approximately 50% of the circulating drug is bound to plasma proteins.</p>
<p><span class="Bold">Metabolism:</span> The major biotransformation pathways for pravastatin are: (a) isomerization to 6-epi pravastatin and the 3Î±-hydroxyisomer of pravastatin (SQ 31,906) and (b) enzymatic ring hydroxylation to SQ 31,945. The 3Î±-hydroxyisomeric metabolite (SQ 31,906) has 1/10 to 1/40 the HMG-CoA reductase inhibitory activity of the parent compound. Pravastatin undergoes extensive first-pass extraction in the liver (extraction ratio 0.66).</p>
<p><span class="Bold">Excretion: </span> Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration of radiolabeled pravastatin to normal volunteers, approximately 47% of total body clearance was via renal excretion and 53% by non-renal routes (i.e., biliary excretion and biotransformation). </p>
<p>Following single dose oral administration of <span class="Sup">14</span>C-pravastatin, the radioactive elimination t<span class="Sub">Â½</span> for pravastatin is 1.8 hours in humans.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s12.3.2"></a><a name="section-11.2.2"></a><p></p>
<h3>Specific Populations</h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> A single 20 mg oral dose of pravastatin was administered to 24 patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (as determined by creatinine clearance). No effect was observed on the pharmacokinetics of pravastatin or its 3Î±-hydroxy isomeric metabolite (SQ 31,906). Compared to healthy subjects with normal renal function, patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had 69% and 37% higher mean AUC and C<span class="Sub">max</span> values, respectively, and a 0.61 hour shorter t<span class="Sub">Â½</span> for the inactive enzymatic ring hydroxylation metabolite (SQ 31,945).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span> In a study comparing the kinetics of pravastatin in patients with biopsy confirmed cirrhosis (N=7) and normal subjects (N=7), the mean AUC varied 18-fold in cirrhotic patients and 5-fold in healthy subjects. Similarly, the peak pravastatin values varied 47-fold for cirrhotic patients compared to 6-fold for healthy subjects. [See <span class="Italics"><a href="#s5.2">Warnings and Precautions (5.2)</a></span>.]</p>
<p><span class="Bold">Geriatric: </span>In a single oral dose study using pravastatin 20 mg, the mean AUC for pravastatin was approximately 27% greater and the mean cumulative urinary excretion (CUE) approximately 19% lower in elderly men (65-75 years old) compared with younger men (19-31 years old). In a similar study conducted in women, the mean AUC for pravastatin was approximately 46% higher and the mean CUE approximately 18% lower in elderly women (65-78 years old) compared with younger women (18-38 years old). In both studies, C<span class="Sub">max</span>, T<span class="Sub">max</span>, and t<span class="Sub">Â½</span> values were similar in older and younger subjects. [See <span class="Italics"><a href="#s8.5">Use in Specific Populations (8.5)</a></span>.]</p>
<p><span class="Bold">Pediatric: </span>After 2 weeks of once-daily 20 mg oral pravastatin administration, the geometric means of AUC were 80.7 (CV 44%) and 44.8 (CV 89%) ng*hr/mL for children (8-11 years, N=14) and adolescents (12-16 years, N=10), respectively. The corresponding values for C<span class="Sub">max</span> were 42.4 (CV 54%) and 18.6 ng/mL (CV 100%) for children and adolescents, respectively. No conclusion can be made based on these findings due to the small number of samples and large variability. [See <span class="Italics"><a href="#s8.4">Use in Specific Populations (8.4)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s12.3.3"></a><a name="section-11.2.3"></a><p></p>
<h3>Drug-Drug Interactions</h3>
<a name="st3"></a><table border="0" cellpadding="2" cellspacing="1" frame="above" width="100%">
<caption><span>Table 3: Effect of Coadministered Drugs on the Pharmacokinetics of Pravastatin</span></caption>
<colgroup>
<col width="31%">
<col width="23%">
<col width="23%">
<col width="23%">
</colgroup>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule">Â </th>
<th class="Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Pravastatin</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Coadministered Drug and Dosing Regimen</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Dose (mg)</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Change in AUC</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Change in C<span class="Sub">max</span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4">BID = twice daily; OD = once daily; QID = four times daily</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">Cyclosporine 5 mg/kg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘282%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘327%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Clarithromycin 500 mg BID for 9 days</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg OD for 8 days</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘110%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘128%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Boceprevir 800 mg TID for 6 days</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘63%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘49%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Darunavir 600 mg BID/Ritonavir 100 mg BID for 7 days</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘81%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘63%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Colestipol 10 g single dose</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†“47%</td>
<td class="Botrule Rrule" align="center" valign="top">â†“53%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Cholestyramine 4 g single dose
<br>Â Â Â Â Administered simultaneously
    	<br>Â Â Â Â Administered 1 hour prior to cholestyramine
    	<br>Â Â Â Â Administered 4 hours after cholestyramine</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>â†“40%<br>â†‘12%<br><br>â†“12%</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>â†“39%<br>â†‘30%<br><br>â†“6.8%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Cholestyramine 24 g OD for 4 weeks</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg BID for 8 weeks<br>5 mg BID for 8 weeks<br>10 mg BID for 8 weeks</td>
<td class="Botrule Rrule" align="center" valign="top">â†“51%<br>â†“38%<br>â†“18%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘4.9%<br>â†‘23%<br>â†“33%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fluconazole
<br>Â Â Â Â 200 mg IV for 6 days
    	<br>Â Â Â Â 200 mg PO for 6 days</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>20 mg PO+10 mg IV<br>20 mg PO+10 mg IV</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>â†“34%<br>â†“16%</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>â†“33%<br>â†“16%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Kaletra 400 mg/100 mg BID for 14 days</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg OD for 4 days</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘33%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘26%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Verapamil IR 120 mg for 1 day and <br>Verapamil ER 480 mg for 3 days</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘31%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘42%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Cimetidine 300 mg QID for 3 days</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘30%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘9.8%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Antacids 15 mL QID for 3 days</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†“28%</td>
<td class="Botrule Rrule" align="center" valign="top">â†“24%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Digoxin 0.2 mg OD for 9 days </td>
<td class="Botrule Rrule" align="center" valign="top">20 mg OD for 9 days</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘23%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘26%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Probucol  500 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘14%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘24%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Warfarin 5 mg OD for 6 days</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg BID for 6 days</td>
<td class="Botrule Rrule" align="center" valign="top">â†“13%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘6.7%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Itraconazole 200 mg OD for 30 days</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg OD for 30 days</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘11% (compared to Day 1)</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘17% (compared to Day 1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Gemfibrozil 600 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†“7.0%</td>
<td class="Botrule Rrule" align="center" valign="top">â†“20%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Aspirin 324 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘4.7%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘8.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Niacin 1 g single dose</td>
<td class="Botrule Rrule" align="center" valign="top ">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†“3.6%</td>
<td class="Botrule Rrule" align="center" valign="top">â†“8.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Diltiazem</td>
<td class="Botrule Rrule" align="center" valign="top ">20 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘2.7%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘30%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Grapefruit juice</td>
<td class="Botrule Rrule" align="center" valign="top">40 mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†“1.8%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘3.7%</td>
</tr>
</tbody>
</table>
<a name="st4"></a><table border="0" cellpadding="2" cellspacing="1" frame="above" width="100%">
<caption><span>Table 4: Effect of Pravastatin on the Pharmacokinetics of Coadministered Drugs</span></caption>
<colgroup>
<col width="31%">
<col width="23%">
<col width="23%">
<col width="23%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold">Pravastatin Dosing Regimen</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Name and Dose</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Change in AUC</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Change in C<span class="Sub">max</span></span></th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="4">BID = twice daily; OD = once daily</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">20 mg BID for 6 days</td>
<td class="Botrule Rrule" align="center" valign="top">Warfarin 5 mg OD for 6 days<br>Change in mean <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘17%<br>â†‘0.4 sec</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘15%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">20 mg OD for 9 days</td>
<td class="Botrule Rrule" align="center" valign="top">Digoxin 0.2 mg OD for 9 days</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘4.6%</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘5.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">20 mg BID for 4 weeks<br>10 mg BID for 4 weeks<br>5 mg BID for 4 weeks</td>
<td class="Botrule Rrule" align="center" valign="top">Antipyrine 1.2 g single dose</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘3.0%<br>â†‘1.6%<br>â†‘ Less than 1%</td>
<td class="Botrule Rrule" align="center" valign="top">Not Reported</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">20 mg OD for 4 days</td>
<td class="Botrule Rrule" align="center" valign="top">Kaletra 400 mg/100 mg BID for 14 days</td>
<td class="Botrule Rrule" align="center" valign="top">No change</td>
<td class="Botrule Rrule" align="center" valign="top">No change</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 2-year study in rats fed pravastatin at doses of 10, 30, or 100 mg/kg body weight, there was an increased incidence of hepatocellular carcinomas in males at the highest dose (p&lt;0.01). These effects in rats were observed at approximately 12 times the human dose (HD) of 80 mg based on body surface area (mg/m<span class="Sup">2</span>) and at approximately 4 times the HD, based on AUC.</p>
<p>In a 2-year study in mice fed pravastatin at doses of 250 and 500 mg/kg/day, there was an increased incidence of hepatocellular carcinomas in males and females at both 250 and 500 mg/kg/day (p&lt;0.0001). At these doses, lung <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in females were increased (p=0.013). These effects in mice were observed at approximately 15 times (250 mg/kg/day) and 23 times (500 mg/kg/day) the HD of 80 mg, based on AUC. In another 2-year study in mice with doses up to 100 mg/kg/day (producing drug exposures approximately 2 times the HD of 80 mg, based on AUC), there were no drug-induced tumors.</p>
<p>No evidence of mutagenicity was observed <span class="Italics">in vitro</span>, with or without
rat-liver metabolic activation, in the following studies: microbial mutagen tests, using mutant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> or <span class="Italics">Escherichia coli</span>; a forward mutation assay in L5178Y TK +/âˆ’ mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells; a chromosomal aberration test in hamster cells; and a gene conversion assay using <span class="Italics">Saccharomyces cerevisiae</span>. In addition, there was no
evidence of mutagenicity in either a dominant lethal test in mice or a micronucleus test in mice.</p>
<p>In a fertility study in adult rats with daily doses up to 500 mg/kg, pravastatin did not produce any adverse effects on fertility or general reproductive performance. </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<div class="Section" data-sectionCode="34091-9">
<a name="s13.2.1"></a><a name="section-12.2.1"></a><p></p>
<h3>CNS Toxicity</h3>
<p class="First">CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and mononuclear cell infiltration of perivascular spaces, were seen in dogs treated with pravastatin at a dose of 25 mg/kg/day. These effects in dogs were observed at approximately 59 times the HD of 80 mg/day, based on AUC. Similar CNS vascular lesions have been observed with several other drugs in this class.</p>
<p>A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion starting at 60 mg/kg/day, a dose that produced mean plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose (as measured by total enzyme inhibitory activity). This same drug also produced vestibulocochlear Wallerian-like degeneration and retinal <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> cell chromatolysis in dogs treated for 14 weeks at 180 mg/kg/day, a dose which resulted in a mean plasma drug level similar to that seen with the 60 mg/kg/day dose.</p>
<p>When administered to juvenile rats (postnatal days [PND] 4 through 80 at 5-45 mg/kg/day), no drug related changes were observed at 5 mg/kg/day. At 15 and 45 mg/kg/day, altered body-<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was observed during the dosing and 52-day recovery periods as well as slight thinning of the corpus callosum at the end of the recovery period. This finding was not evident in rats examined at the completion of the dosing period and was not associated with any inflammatory or degenerative changes in the brain. The biological relevance of the corpus callosum finding is uncertain due to the absence of any other microscopic changes in the brain or peripheral nervous tissue and because it occurred at the end of the recovery period. Neurobehavioral changes (enhanced acoustic startle responses and increased errors in water-maze learning) combined with evidence of generalized toxicity were noted at 45 mg/kg/day during the later part of the recovery period. Serum pravastatin levels at 15 mg/kg/day are approximately â‰¥1 times (AUC) the maximum pediatric dose of 40 mg. No thinning of the corpus callosum was observed in rats dosed with pravastatin (â‰¥250 mg/kg/day) beginning PND 35 for 3 months suggesting increased sensitivity in younger rats. PND 35 in a rat is approximately equivalent to an 8- to 12-year-old human child.  Juvenile male rats given 90 times (AUC) the 40 mg dose had decreased fertility (20%) with sperm abnormalities compared to controls.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="s14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Prevention of Coronary Heart Disease</h2>
<p class="First">In the Pravastatin Primary Prevention
Study (WOS),<span class="Sup">3</span> the effect of PRAVACHOL on fatal
and nonfatal CHD was assessed in 6595 men 45 to 64 years of age, without a
previous MI, and with LDL-C levels between 156 to 254 mg/dL (4-6.7 mmol/L).
In this randomized, double-blind, placebo-controlled study, patients were
treated with standard care, including dietary advice, and either PRAVACHOL
40 mg daily (N=3302) or placebo (N=3293) and followed for a median duration
of 4.8 years. Median (25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile)
percent changes from baseline after 6 months of pravastatin treatment in Total-C,
LDL-C, TG, and HDL-C were âˆ’20.3 (âˆ’26.9, âˆ’11.7), âˆ’27.7 (âˆ’36.0, âˆ’16.9), âˆ’9.1
(âˆ’27.6, 12.5), and 6.7 (âˆ’2.1, 15.6), respectively.</p>
<p>PRAVACHOL
significantly reduced the rate of first coronary events (either CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>
or nonfatal MI) by 31% (248 events in the placebo group [CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>=44, nonfatal
MI=204] versus 174 events in the PRAVACHOL group [CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>=31, nonfatal MI=143],
p=0.0001 [see figure below]). The risk reduction with PRAVACHOL was similar
and significant throughout the entire range of baseline LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels.
This reduction was also similar and significant across the age range studied
with a 40% risk reduction for patients younger than 55 years and a 27% risk
reduction for patients 55 years and older. The Pravastatin Primary Prevention
Study included only men, and therefore it is not clear to what extent these
data can be extrapolated to a similar population of female patients. </p>
<div class="Figure"><img alt="Pravachol Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=897ad8b7-921d-eb02-a61c-3419e662a2da&amp;name=pravachol-fig1.jpg"></div>
<p>PRAVACHOL also significantly decreased the risk for undergoing
myocardial revascularization procedures (coronary artery bypass graft [CABG]
surgery or percutaneous transluminal coronary angioplasty [PTCA]) by 37% (80
vs 51 patients, p=0.009) and coronary angiography by 31% (128 vs 90, p=0.007).
Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were decreased by 32% (73Â vs 50, p=0.03)
and there was no increase in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from non-cardiovascular causes.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2  Secondary Prevention of Cardiovascular Events</h2>
<p class="First">In the LIPID<span class="Sup">4</span> study,
the effect of PRAVACHOL, 40 mg daily, was assessed in 9014 patients (7498
men; 1516 women; 3514 elderly patients [age â‰¥65 years]; 782 diabetic patients)
who had experienced either an MI (5754 patients) or had been hospitalized
for <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> pectoris (3260 patients) in the preceding 3 to 36 months.
Patients in this multicenter, double-blind, placebo-controlled study participated
for an average of 5.6 years (median of 5.9 years) and at randomization had
Total-C between 114 and 563 mg/dL (mean 219 mg/dL), LDL-C between 46 and 274
mg/dL (mean 150Â mg/dL), TG between 35 and 2710 mg/dL (mean
160 mg/dL), and HDL-C between 1 and 103 mg/dL (mean 37 mg/dL). At baseline,
82% of patients were receiving aspirin and 76% were receiving antihypertensive
medication. Treatment with PRAVACHOL significantly reduced the risk for total
mortality by reducing coronary <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see <a href="#st5">Table 5</a>).
The risk reduction due to treatment with PRAVACHOL on CHD mortality was consistent
regardless of age. PRAVACHOL significantly reduced the risk for total mortality
(by reducing CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and CHD events (CHD mortality or nonfatal MI) in patients
who qualified with a history of either MI or hospitalization for unstable
<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.</p>
<a name="st5"></a><table border="0" cellpadding="2" cellspacing="1" frame="above" width="100%">
<caption><span>Table 5: LIPID - Primary and Secondary Endpoints</span></caption>
<colgroup>
<col width="27%">
<col width="16%">
<col width="16%">
<col width="16%">
<col width="16%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left"></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Number
(%) of Subjects </span></th>
<th class="Botrule Rrule Toprule" align="left" colspan="2"></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="Bold">Event</span></th>
<th class="Botrule Rrule" align="center"><span class="Bold">Pravastatin 40
mg<br>(N=4512)</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo<br> (N=4502)</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">Risk<br>Reduction</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold"><span class="Bold Italics">p</span>-value </span></th>
</tr>
</thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="5"><span class="Bold">Primary
Endpoint</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Â Â Â Â CHD
mortality</td>
<td class="Rrule" align="center">287 (6.4)</td>
<td class="Rrule" align="center">373 (8.3)</td>
<td class="Rrule" align="center">24%</td>
<td class="Rrule" align="center">0.0004</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="5"><span class="Bold">Secondary
Endpoints </span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Â Â Â Â Total
mortality</td>
<td class="Botrule Rrule" align="center">498 (11.0)</td>
<td class="Botrule Rrule" align="center">633 (14.1)</td>
<td class="Botrule Rrule" align="center">23%</td>
<td class="Botrule Rrule" align="center">&lt;0.0001</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Â Â Â Â CHD
mortality or nonfatal MI </td>
<td class="Botrule Rrule" align="center">557 (12.3)</td>
<td class="Botrule Rrule" align="center">715 (15.9)</td>
<td class="Botrule Rrule" align="center">24%</td>
<td class="Botrule Rrule" align="center">&lt;0.0001</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Â Â Â Â Myocardial
revascularization<br>Â Â Â Â procedures
(CABG or PTCA)</td>
<td class="Botrule Rrule" align="center">584 (12.9)</td>
<td class="Botrule Rrule" align="center">706 (15.7)</td>
<td class="Botrule Rrule" align="center">20%</td>
<td class="Botrule Rrule" align="center">&lt;0.0001</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="5">Â Â Â Â <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Â Â Â Â Â Â Â Â All-cause</td>
<td class="Botrule Rrule" align="center">169 (3.7)</td>
<td class="Botrule Rrule" align="center">204 (4.5)</td>
<td class="Botrule Rrule" align="center">19%</td>
<td class="Botrule Rrule" align="center">0.0477</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Â Â Â Â Â Â Â Â Non-hemorrhagic</td>
<td class="Botrule Rrule" align="center">154 (3.4)</td>
<td class="Botrule Rrule" align="center">196 (4.4)</td>
<td class="Botrule Rrule" align="center">23%</td>
<td class="Botrule Rrule" align="center">0.0154</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Â Â Â Â Cardiovascular
mortality</td>
<td class="Botrule Rrule" align="center">331 (7.3)</td>
<td class="Botrule Rrule" align="center">433 (9.6)</td>
<td class="Botrule Rrule" align="center">25%</td>
<td class="Botrule Rrule" align="center">&lt;0.0001</td>
</tr>
</tbody>
</table>
<p>In the CARE<span class="Sup">5</span> study, the effect
of PRAVACHOL, 40Â mg daily, on CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and nonfatal MI was assessed in 4159
patients (3583 men and 576 women) who had experienced a MI in the preceding
3 to 20 months and who had normal (below the 75<span class="Sup">th</span> percentile
of the general population) plasma total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. Patients in this
double-blind, placebo-controlled study participated for an average of 4.9
years and had a mean baseline Total-C of 209 mg/dL. LDL-C levels in this patient
population ranged from 101 to 180 mg/dL (mean 139 mg/dL). At baseline, 84%
of patients were receiving aspirin and 82% were taking antihypertensive medications.
Median (25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile)
percent changes from baseline after 6 months ofÂ pravastatin
treatment in Total-C, LDL-C, TG, and HDL-C were âˆ’22.0 (âˆ’28.4, âˆ’14.9), âˆ’32.4
(âˆ’39.9, âˆ’23.7), âˆ’11.0 (âˆ’26.5, 8.6), and 5.1 (âˆ’2.9, 12.7), respectively. Treatment
with PRAVACHOL significantly reduced the rate of first recurrent coronary
events (either CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or nonfatal MI), the risk of undergoing revascularization
procedures (PTCA, CABG), and the risk for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA (see <a href="#st6">Table
6</a>).</p>
<a name="st6"></a><table border="0" cellpadding="2" cellspacing="1" frame="box" width="100%">
<caption><span>Table 6: CARE - Primary and Secondary Endpoints</span></caption>
<colgroup>
<col width="27%">
<col width="16%">
<col width="16%">
<col width="16%">
<col width="16%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Number
(%) of Subjects</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2"></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="Bold">Event</span></th>
<th class="Botrule Rrule" align="center"><span class="Bold">Pravastatin 40
mg<br>(N=2081)</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo<br>(N=2078)</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">Risk<br>Reduction</span></th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold"><span class="Bold Italics">p</span>-value </span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="5">
<span class="Sup">a</span>Â Â The
risk reduction due to treatment with PRAVACHOL was consistent in both sexes.</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="5"><span class="Bold">Primary
Endpoint</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Â Â CHD
mortality or nonfatal MI<span class="Sup">a</span>
</td>
<td class="Rrule" align="center">212 (10.2)</td>
<td class="Rrule" align="center">274 (13.2)</td>
<td class="Rrule" align="center">24%</td>
<td class="Rrule" align="center">0.003</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="5"><span class="Bold">Secondary
Endpoints</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Â Â Myocardial
revascularization procedures (CABG or PTCA)</td>
<td class="Rrule" align="center">294 (14.1)</td>
<td class="Rrule" align="center">391 (18.8)</td>
<td class="Rrule" align="center">27%</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>
or TIA</td>
<td class="Botrule Rrule Toprule" align="center">93 (4.5)</td>
<td class="Botrule Rrule Toprule" align="center">124 (6.0)</td>
<td class="Botrule Rrule Toprule" align="center">26%</td>
<td class="Botrule Rrule Toprule" align="center">0.029</td>
</tr>
</tbody>
</table>
<p>In the PLAC I<span class="Sup">6</span> study, the effect
of pravastatin therapy on <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span> was assessed by coronary
angiography in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary disease</span> and moderate <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>
(baseline LDL-C range: 130-190 mg/dL). In this double-blind, multicenter,
controlled clinical trial, angiograms were evaluated at baseline and at 3
years in 264 patients. Although the difference between pravastatin and placebo
for the primary endpoint (per-patient change in mean coronary artery diameter)
and 1 of 2 secondary endpoints (change in percent lumen diameter stenosis)
did not reach statistical significance, for the secondary endpoint of change
in minimum lumen diameter, statistically significant slowing of disease was
seen in the pravastatin treatment group (p=0.02).</p>
<p>In
the REGRESS<span class="Sup">7</span> study, the effect of pravastatin on
<span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span> was assessed by coronary angiography in 885 patients
with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, angiographically documented <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>,
and <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (baseline total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> range: 160-310Â mg/dL).
In this double-blind, multicenter, controlled clinical trial, angiograms were
evaluated at baseline and at 2 years in 653 patients (323 treated with pravastatin).
Progression of <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span> was significantly slowed in the pravastatin
group as assessed by changes in mean segment diameter (p=0.037) and minimum
obstruction diameter (p=0.001).</p>
<p>Analysis of pooled
events from PLAC I, PLAC II,<span class="Sup">8</span> REGRESS, and KAPS<span class="Sup">9</span> studies
(combined N=1891) showed that treatment with pravastatin was associated with
a statistically significant reduction in the composite event rate of fatal
and nonfatal MI (46 events or 6.4% for placebo versus 21 events or 2.4% for
pravastatin, p=0.001). The predominant effect of pravastatin was to reduce
the rate of nonfatal MI.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3  Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (<span class="Italics">Fredrickson</span> Types IIa and IIb)</h2>
<p class="First">PRAVACHOL is highly effective in reducing
Total-C, LDL-C, and TG in patients with heterozygous familial, presumed familial
combined, and non-familial (non-FH) forms of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>,
and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. A therapeutic response is seen within 1 week, and
the maximum response usually is achieved within 4 weeks. This response is
maintained during extended periods of therapy. In addition, PRAVACHOL is effective
in reducing the risk of acute coronary events in hypercholesterolemic patients
with and without previous MI.</p>
<p>A single daily dose is
as effective as the same total daily dose given twice a day. In multicenter,
double-blind, placebo-controlled studies of patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>,
treatment with pravastatin in daily doses ranging from 10 to 40Â mg consistently
and significantly decreased Total-C, LDL-C, TG, and Total-C/HDL-C and LDL-C/HDL-C
ratios (see <a href="#st7">Table 7</a>).</p>
<p>In a
pooled analysis of 2 multicenter, double-blind, placebo-controlled studies
of patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, treatment with pravastatin
at a daily dose of 80 mg (N=277) significantly decreased Total-C, LDL-C, and
TG. The 25<span class="Sup">th</span> and 75<span class="Sup">th</span> percentile
changes from baseline in LDL-C for pravastatin 80 mg were âˆ’43% and âˆ’30%. The
efficacy results of the individual studies were consistent with the pooled
data (see <a href="#st7">Table 7</a>).</p>
<p>Treatment
with PRAVACHOL modestly decreased VLDL-C and PRAVACHOL across all doses produced
variable increases in HDL-C (see <a href="#st7">Table 7</a>).</p>
<a name="st7"></a><table border="0" cellpadding="2" cellspacing="1" frame="box" width="100%">
<caption><span>Table 7: Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> Studies: Dose Response of PRAVACHOL
Once Daily Administration</span></caption>
<tfoot>
<tr class="First"><td align="left" colspan="5">
<span class="Sup">a</span>Â Â A
multicenter, double-blind, placebo-controlled study.</td></tr>
<tr class="Last"><td align="left" colspan="5">
<span class="Sup">b</span>Â Â Pooled
analysis of 2 multicenter, double-blind, placebo-controlled studies.</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left">Dose</th>
<th class="Botrule Rrule Toprule" align="center">Total-C</th>
<th class="Botrule Rrule Toprule" align="center">LDL-C</th>
<th class="Botrule Rrule Toprule" align="center">HDL-C</th>
<th class="Botrule Rrule Toprule" align="center">TG</th>
</tr>
<tr>
<td class="Botrule Lrule">Â </td>
<td class="Botrule Rrule" align="center" colspan="4">Mean Percent Changes
From Baseline After 8 Weeks<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Placebo (N=36)</td>
<td class="Botrule Rrule" align="center">âˆ’3%</td>
<td class="Botrule Rrule" align="center">âˆ’4%</td>
<td class="Botrule Rrule" align="center">+1%</td>
<td class="Botrule Rrule" align="center">âˆ’4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">10 mg (N=18)</td>
<td class="Botrule Rrule" align="center">âˆ’16%</td>
<td class="Botrule Rrule" align="center">âˆ’22%</td>
<td class="Botrule Rrule" align="center">+7%</td>
<td class="Botrule Rrule" align="center">âˆ’15%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">20 mg (N=19)</td>
<td class="Botrule Rrule" align="center">âˆ’24%</td>
<td class="Botrule Rrule" align="center">âˆ’32%</td>
<td class="Botrule Rrule" align="center">+2%</td>
<td class="Botrule Rrule" align="center">âˆ’11%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">40 mg (N=18)</td>
<td class="Botrule Rrule" align="center">âˆ’25%</td>
<td class="Botrule Rrule" align="center">âˆ’34%</td>
<td class="Botrule Rrule" align="center">+12%</td>
<td class="Botrule Rrule" align="center">âˆ’24%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Â </td>
<td class="Botrule Rrule" align="center" colspan="4">Mean Percent Changes
From Baseline After 6 Weeks<span class="Sup">b</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Placebo (N=162)</td>
<td class="Botrule Rrule" align="center">0%</td>
<td class="Botrule Rrule" align="center">âˆ’1%</td>
<td class="Botrule Rrule" align="center">âˆ’1%</td>
<td class="Botrule Rrule" align="center">+1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">80 mg (N=277)</td>
<td class="Botrule Rrule" align="center">âˆ’27%</td>
<td class="Botrule Rrule" align="center">âˆ’37%</td>
<td class="Botrule Rrule" align="center">+3%</td>
<td class="Botrule Rrule" align="center">âˆ’19%</td>
</tr>
</tbody>
</table>
<p>In another clinical trial, patients treated with pravastatin
in combination with cholestyramine (70% of patients were taking cholestyramine
20 or 24 g per day) had reductions equal to or greater than 50% in LDL-C.
Furthermore, pravastatin attenuated cholestyramine-induced increases in TG
levels (which are themselves of uncertain clinical significance).</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4  <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (<span class="Italics">Fredrickson</span> Type IV)</h2>
<p class="First">The response to pravastatin in patients
with Type IV <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (baseline TG &gt;200Â mg/dL and LDL-C &lt;160 mg/dL)
was evaluated in a subset of 429 patients from the CARE study. For pravastatin-treated
subjects, the median (min, max) baseline TG level was 246.0 (200.5, 349.5)
mg/dL (see <a href="#st8">Table 8</a>.)</p>
<a name="st8"></a><table border="0" cellpadding="2" cellspacing="1" frame="box" width="100%">
<caption><span>Table 8: Patients with Fredrickson Type IV <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> Median
(25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentile) % Change from Baseline</span></caption>
<colgroup>
<col width="28%">
<col width="36%">
<col width="36%">
</colgroup>
<tbody class="Headless"><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left">Â </th>
<th class="Botrule Rrule Toprule" align="center">Pravastatin 40 mg (N=429)</th>
<th class="Botrule Rrule Toprule" align="center">Placebo (N=430)</th>
</tr></tbody>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">TG</td>
<td class="Botrule Rrule" align="center">âˆ’21.1 (âˆ’34.8, 1.3)</td>
<td class="Botrule Rrule" align="center">âˆ’6.3 (âˆ’23.1, 18.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Total-C</td>
<td class="Botrule Rrule" align="center">âˆ’22.1 (âˆ’27.1, âˆ’14.8)</td>
<td class="Botrule Rrule" align="center">0.2 (âˆ’6.9, 6.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">LDL-C</td>
<td class="Botrule Rrule" align="center">âˆ’31.7 (âˆ’39.6, âˆ’21.5)</td>
<td class="Botrule Rrule" align="center">0.7 (âˆ’9.0, 10.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">HDL-C</td>
<td class="Botrule Rrule" align="center">7.4 (âˆ’1.2, 17.7)</td>
<td class="Botrule Rrule" align="center">2.8 (âˆ’5.7, 11.7)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Non-HDL-C</td>
<td class="Botrule Rrule" align="center">âˆ’27.2 (âˆ’34.0, âˆ’18.5)</td>
<td class="Botrule Rrule" align="center">âˆ’0.8 (âˆ’8.2, 7.0)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5  Dysbetalipoproteinemia (<span class="Italics">Fredrickson</span> Type III)</h2>
<p class="First">The response to pravastatin in two double-blind
crossover studies of 46 patients with genotype E2/E2 and <span class="Italics">Fredrickson</span> Type
III dysbetalipoproteinemia is shown in <a href="#st9">Table 9</a>.</p>
<a name="st9"></a><table border="0" cellpadding="2" cellspacing="1" frame="above" width="100%">
<caption><span>Table 9: Patients with Fredrickson Type III Dysbetalipoproteinemia
Median (min, max) % Change from Baseline</span></caption>
<colgroup>
<col width="28%">
<col width="36%">
<col width="36%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â </td>
<td class="Botrule Rrule Toprule" align="center">Median (min, max)<br>at
Baseline (mg/dL)</td>
<td class="Botrule Rrule Toprule" align="center">Median % Change (min, max)<br>Pravastatin
40 mg (N=20)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">Study 1</span></td>
<td class="Botrule" align="center">Â </td>
<td class="Botrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Total-C</td>
<td class="Botrule Lrule Rrule Toprule" align="center">386.5 (245.0, 672.0)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">âˆ’32.7 (âˆ’58.5, 4.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">TG</td>
<td class="Botrule Rrule" align="center">443.0 (275.0, 1299.0)</td>
<td class="Botrule Rrule" align="center">âˆ’23.7 (âˆ’68.5, 44.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">VLDL-C<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">206.5 (110.0, 379.0)</td>
<td class="Botrule Rrule" align="center">âˆ’43.8 (âˆ’73.1, âˆ’14.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">LDL-C<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">117.5 (80.0, 170.0)</td>
<td class="Botrule Rrule" align="center">âˆ’40.8 (âˆ’63.7, 4.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">HDL-C</td>
<td class="Botrule Rrule" align="center">30.0 (18.0, 88.0)</td>
<td class="Botrule Rrule" align="center">6.4 (âˆ’45.0, 105.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Non-HDL-C</td>
<td class="Botrule Rrule" align="center">344.5 (215.0, 646.0)</td>
<td class="Botrule Rrule" align="center">âˆ’36.7 (âˆ’66.3, 5.8)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3">
<span class="Sup">a</span>Â Â N=14</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Â </td>
<td class="Botrule Rrule" align="center">Median (min, max)<br>at
Baseline (mg/dL)</td>
<td class="Botrule Rrule" align="center">Median % Change (min, max)<br>Pravastatin
40 mg (N=26)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Italics">Study 2</span></td>
<td class="Botrule" align="center">Â </td>
<td class="Botrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Total-C</td>
<td class="Botrule Rrule" align="center">340.3 (230.1, 448.6)</td>
<td class="Botrule Rrule" align="center">âˆ’31.4 (âˆ’54.5, âˆ’13.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">TG</td>
<td class="Botrule Rrule" align="center">343.2 (212.6, 845.9)</td>
<td class="Botrule Rrule" align="center">âˆ’11.9 (âˆ’56.5, 44.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">VLDL-C</td>
<td class="Botrule Rrule" align="center">145.0 (71.5, 309.4)</td>
<td class="Botrule Rrule" align="center">âˆ’35.7 (âˆ’74.7, 19.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">LDL-C</td>
<td class="Botrule Rrule" align="center">128.6 (63.8, 177.9)</td>
<td class="Botrule Rrule" align="center">âˆ’30.3 (âˆ’52.2, 13.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">HDL-C</td>
<td class="Botrule Rrule" align="center">38.7 (27.1, 58.0)</td>
<td class="Botrule Rrule" align="center">5.0 (âˆ’17.7, 66.7)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Non-HDL-C</td>
<td class="Botrule Rrule" align="center">295.8 (195.3, 421.5)</td>
<td class="Botrule Rrule" align="center">âˆ’35.5 (âˆ’81.0, âˆ’13.5)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14.6"></a><a name="section-13.6"></a><p></p>
<h2>14.6  Pediatric Clinical Study</h2>
<p class="First">A double-blind, placebo-controlled study
in 214 patients (100 boys and 114 girls) with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span>
(HeFH), aged 8 to 18 years was conducted for 2 years. The children (aged 8-13
years) were randomized to placebo (N=63) or 20Â mg of pravastatin daily (N=65)
and the adolescents (aged 14-18 years) were randomized to placebo (N=45) or
40 mg of pravastatin daily (N=41). Inclusion in the study required an LDL-C
level &gt;95<span class="Sup">th</span> percentile for age and sex and one
parent with either a clinical or molecular diagnosis of familial <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>.
The mean baseline LDL-C value was 239 mg/dL and 237Â mg/dL
in the pravastatin (range: 151-405 mg/dL) and placebo (range: 154-375 mg/dL)
groups, respectively.</p>
<p>Pravastatin significantly decreased
plasma levels of LDL-C, Total-C, and ApoB in both children and adolescents
(see <a href="#st10">Table 10</a>). The effect of pravastatin treatment
in the 2 age groups was similar.</p>
<a name="st10"></a><table border="0" cellpadding="2" cellspacing="1" frame="above" width="100%">
<caption><span>Table 10: Lipid-Lowering Effects of Pravastatin in Pediatric Patients
 with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span>: Least-Squares Mean % Change
from Baseline at Month 24 (Last Observation Carried Forward: Intent-to-Treat)<span class="Sup">a</span></span></caption>
<colgroup>
<col width="15%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="20%">
<col width="20%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule"></th>
<th class="Botrule Rrule Toprule" align="center"><span class="Bold">Pravastatin<br>20
mg<br>(Aged 8-13<br>years)<br>N=65 </span></th>
<th class="Botrule Rrule Toprule" align="center"><span class="Bold">Pravastatin<br>40
mg<br>(Aged 14-18<br>years)<br>N=41 </span></th>
<th class="Botrule Rrule Toprule" align="center"><span class="Bold">Combined<br>Pravastatin<br>(Aged
8-18<br>years)<br>N=106 </span></th>
<th class="Botrule Rrule Toprule" align="center"><span class="Bold">Combined<br>Placebo<br>(Aged
8-18<br>years)<br>N=108 </span></th>
<th class="Botrule Rrule Toprule" align="center"><span class="Bold">95% CI of the Difference
Between Combined Pravastatin and Placebo</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="6">
<span class="Sup">a</span>Â Â The
above least-squares mean values were calculated based on log-transformed lipid
values.</td></tr>
<tr class="Last"><td align="left" colspan="6">
<span class="Sup">b</span>Â Â Significant
at pâ‰¤0.0001 when compared with placebo.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">LDL-C </span></td>
<td class="Botrule Lrule Rrule" align="center">âˆ’26.04<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’21.07<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’24.07<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’1.52</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’26.74, âˆ’18.86)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">TC </span></td>
<td class="Botrule Lrule Rrule" align="center">âˆ’20.75<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’13.08<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’17.72<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’0.65</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’20.40, âˆ’13.83)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">HDL-C </span></td>
<td class="Botrule Lrule Rrule" align="center">1.04</td>
<td class="Botrule Lrule Rrule" align="center">13.71</td>
<td class="Botrule Lrule Rrule" align="center">5.97</td>
<td class="Botrule Lrule Rrule" align="center">3.13</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’1.71, 7.43)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">TG </span></td>
<td class="Botrule Lrule Rrule" align="center">âˆ’9.58</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’0.30</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’5.88</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’3.27</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’13.95, 10.01)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
<span class="Bold">ApoB</span><br>(N)</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’23.16<span class="Sup">b</span><br>(61)</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’18.08<span class="Sup">b</span><br>(39)</td>
<td class="Botrule Lrule Rrule" align="center">âˆ’21.11<span class="Sup">b</span><br>(100)</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">âˆ’0.97<br>(106)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(âˆ’24.29, âˆ’16.18)</td>
</tr>
</tbody>
</table>
<p>The mean achieved LDL-C was 186 mg/dL (range: 67-363 mg/dL)
in the pravastatin group compared to 236 mg/dL (range: 105-438 mg/dL) in the
placebo group.</p>
<p>The safety and efficacy of pravastatin
doses above 40 mg daily have not been studied in children. The long-term efficacy
of pravastatin therapy in childhood to reduce morbidity and mortality in adulthood
has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s15"></a><a name="section-14"></a><p></p>
<h1>15  REFERENCES<br>
</h1>
<ol class="Arabic">
<li>Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins
- An integrated approach to mechanisms and disorders. <span class="Italics">N Engl J Med</span>.
1967;276: 34-44, 94-103, 148-156, 215-225, 273-281.</li>
<li>Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing
surveillance of lovastatin and simvastatin exposure during pregnancy. <span class="Italics">Reprod
Toxicol</span>. 1996;10(6):439-446.</li>
<li>Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland
Coronary Prevention Study Group (WOS). Prevention of coronary heart disease
with pravastatin in men with <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. <span class="Italics">N Engl J Med</span>.
1995;333:1301-1307.</li>
<li>The Long-term Intervention with Pravastatin in Ischemic
Disease Group (LIPID). Prevention of cardiovascular events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> with
pravastatin in patients with coronary heart disease and a broad range of initial
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. <span class="Italics">N Engl J Med</span>. 1998;339:1349-1357.</li>
<li>Sacks FM, Pfeffer MA, Moye LA, et al, for the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
and Recurrent Events Trial Investigators (CARE). The effect of pravastatin
on coronary events after <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in patients with average <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>
levels. <span class="Italics">N Engl J Med</span>. 1996;335:1001-1009.</li>
<li>Pitt B, Mancini GBJ, Ellis SG, et al, for the PLAC I Investigators.
Pravastatin limitation of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> in the coronary arteries (PLAC I):
Reduction in <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> progression and clinical events. <span class="Italics">J Am
Coll Cardiol</span>. 1995;26:1133-1139.</li>
<li>Jukema JW, Bruschke AVG, van Boven AJ, et al, for the
Regression Growth Evaluation Statin Study Group (REGRESS). Effects of lipid
lowering by pravastatin on progression and regression of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>
in symptomatic man with normal to moderately elevated serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. <span class="Italics">Circ</span>.
1995;91:2528-2540.</li>
<li>Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids,
and <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> in the carotid arteries: Design features of a clinical
trial with carotid <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> outcome (PLAC II). <span class="Italics">Control Clin
Trials</span>. 1992;13:495-506.</li>
<li>Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span>
Prevention Study (KAPS). A population-based primary preventive trial of the
effect of LDL lowering on atherosclerotic progression in carotid and femoral
arteries. <span class="Italics">Circ</span>. 1995;92:1758-1764.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="s16.1"></a><a name="section-15.1"></a><p></p>
<h2>16.1  How Supplied</h2>
<p class="First"><span class="Bold">PRAVACHOL</span><span class="Sup">Â®</span><span class="Bold"> (pravastatin
sodium) Tablets</span> are supplied as:</p>
<p><span class="Bold">10 mg
tablets:</span> Pink to peach, rounded, rectangular-shaped, biconvex with
a â€œPâ€? embossed on one side and â€œPRAVACHOL 10â€? engraved on the opposite side.
They are supplied in bottles of 90 (NDC 0003-5154-05). Bottles contain a desiccant
canister.</p>
<p><span class="Bold">20 mg tablets:</span> Yellow, rounded,
rectangular-shaped, biconvex with a â€œPâ€? embossed on one side and â€œPRAVACHOL
20â€? engraved on the opposite side. They are supplied in bottles of 90 (NDC
0003-5178-05). Bottles contain a desiccant canister.</p>
<p><span class="Bold">40
mg tablets:</span> Green, rounded, rectangular-shaped, biconvex with a â€œPâ€?
embossed on one side and â€œPRAVACHOL 40â€? engraved on the opposite side. They
are supplied in bottles of 90 (NDC 0003-5194-10). Bottles contain a desiccant
canister.</p>
<p><span class="Bold">80 mg tablets:</span> Yellow, oval-shaped
tablet with â€œBMSâ€? on one side and â€œ80â€? on the other side. They are supplied
in bottles of 90 (NDC 0003-5195-10). Bottles contain a desiccant canister.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s16.2"></a><a name="section-15.2"></a><p></p>
<h2>16.2  Storage</h2>
<p class="First">Store at 25Â°C (77Â°F); excursions permitted
to 15Â°C to 30Â°C (59Â°F to 86Â°F) [see USP Controlled Room Temperature]. Keep tightly
closed (protect from moisture). Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s17"></a><a name="section-16"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised to report promptly unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly
if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if these muscle signs or symptoms persist after discontinuing PRAVACHOL [see <span class="Italics"><a href="#s5.1">Warnings
and Precautions (5.1)</a></span>].</p>
<p>It is recommended that liver enzyme tests be performed before the initiation of PRAVACHOL, and thereafter when clinically indicated. All patients treated with PRAVACHOL should be advised to promptly report any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> [see <span class="Italics"><a href="#s5.2">Warnings
and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-17"></a><p></p>
<p class="First"><br><br>Bristol-Myers Squibb Company<br>Princeton, New Jersey 08543 USA<br><br>Product of Japan<br><br>1292354A2<br>Rev August 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s18"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">---------------------------------------------<br>REPRESENTATIVE PACKAGING</span></p>
<p>See 
							<span class="Bold">How Supplied</span> section for a complete list of available packages of PRAVACHOL.
						</p>
<p>90 tablets<br>NDC 0003-5178-05<br>20 mg<br>PRAVACHOL<span class="Sup">Â®</span><br>(pravastatin sodium) Tablets<br>Rx only<br>Bristol-Myers Squibb</p>
<div class="Figure"><img alt="Pravachol 20 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=897ad8b7-921d-eb02-a61c-3419e662a2da&amp;name=pravachol-20mg-lbl.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s21"></a><a name="section-19"></a><p></p>
<p class="First">90 tablets<br>NDC 0003-5194-10<br>40 mg<br>PRAVACHOL<span class="Sup">Â®</span><br>(pravastatin sodium) Tablets<br>Rx only<br>Bristol-Myers Squibb</p>
<div class="Figure"><img alt="Pravachol 40 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=897ad8b7-921d-eb02-a61c-3419e662a2da&amp;name=pravachol-40mg-lbl.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s22"></a><a name="section-20"></a><p></p>
<p class="First">90 tablets<br>NDC 0003-5195-10<br>80 mg<br>PRAVACHOL<span class="Sup">Â®</span><br>(pravastatin sodium) Tablets<br>Rx only<br>Bristol-Myers Squibb</p>
<div class="Figure"><img alt="Pravachol 80 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=897ad8b7-921d-eb02-a61c-3419e662a2da&amp;name=pravachol-80mg-lbl.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRAVACHOLÂ 		
					</strong><br><span class="contentTableReg">pravastatin sodium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-5178</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pravastatin sodium</strong> (pravastatin) </td>
<td class="formItem">pravastatin sodium</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium oxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">RECTANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">P;Pravachol;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-5178-05</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019898</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRAVACHOLÂ 		
					</strong><br><span class="contentTableReg">pravastatin sodium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-5194</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pravastatin sodium</strong> (pravastatin) </td>
<td class="formItem">pravastatin sodium</td>
<td class="formItem">40Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium oxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Yellow No. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>aluminum hydroxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">RECTANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">P;Pravachol;40</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-5194-10</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019898</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRAVACHOLÂ 		
					</strong><br><span class="contentTableReg">pravastatin sodium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-5195</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pravastatin sodium</strong> (pravastatin) </td>
<td class="formItem">pravastatin sodium</td>
<td class="formItem">80Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium oxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong> ferric oxide yellow</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BMS;80</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-5195-10</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019898</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>E.R. Squibb &amp; Sons, L.L.C.
							(011550092)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1df7e691-9b98-43a9-ac46-24fa96652062</div>
<div>Set id: 897ad8b7-921d-eb02-a61c-3419e662a2da</div>
<div>Version: 6</div>
<div>Effective Time: 20130828</div>
</div>
</div>Â <div class="DistributorName">E.R. Squibb &amp; Sons, L.L.C.</div></p>
</body></html>
